VEGFA and macular degeneration: Due to the important role of VEGF in the angiogenesis of oncological diseases or eye diseases (especially macular degeneration of the retina) and the increase in use of VEGF inhibitors (e.g., Bevacizumab) in the treatment of these diseases, the question arises whether these patients, in addition to other undesirable drugs related to the administration of anti-VEGF (cardiotoxicity), will not be at increased risk of the onset and development of invasive GAS infections [79,80].